Scarica l'app Stockscreener
22.44
4.14%
-0.97
Dopo l'orario di chiusura:
22.64
0.20
+0.89%
Precedente Chiudi:
$23.41
Aprire:
$24.2
Volume 24 ore:
1.24M
Relative Volume:
0.60
Capitalizzazione di mercato:
$2.48B
Reddito:
$12.59M
Utile/perdita netta:
$-212.39M
Rapporto P/E:
-7.2732
EPS:
-3.0853
Flusso di cassa netto:
$-185.92M
1 W Prestazione:
-6.50%
1M Prestazione:
+9.09%
6M Prestazione:
+126.44%
1 anno Prestazione:
+115.77%
Intervallo 1D:
$22.25
$24.25
Intervallo di 1 settimana:
$22.25
$25.76
Portata 52W:
$5.1501
$27.65
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
22.44 | 2.58B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Iniziato | Truist | Buy |
| 2025-09-22 | Iniziato | Goldman | Buy |
| 2025-09-05 | Iniziato | Craig Hallum | Buy |
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
HC Wainwright Initiates Immunome at Buy With $40 Price Target - marketscreener.com
Immunome (IMNM) Initiates Coverage with a Buy Rating by HC Wainw - GuruFocus
H.C. Wainwright initiates coverage on Immunome stock with Buy rating By Investing.com - Investing.com India
Immunome (IMNM): Biotech minnow in the spotlight as volatility returns to cancer drug hunters - AD HOC NEWS
Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM - MarketBeat
Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 5, 2026 - BioSpace
Immunome reports inducement grants under Nasdaq listing rule - marketscreener.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - BioSpace
Short Covering: Is Immunome Inc affected by consumer sentimentM&A Rumor & Consistent Profit Alerts - baoquankhu1.vn
Immunome (IMNM) Receives a Buy from Wedbush - The Globe and Mail
Immunome stock hits 52-week high at $26.74 By Investing.com - Investing.com Canada
Immunome (NASDAQ:IMNM) Hits New 1-Year HighWhat's Next? - MarketBeat
Immunome stock hits 52-week high at $26.74 - Investing.com
Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 12.6% in January - MarketBeat
The Insider Report: Batten Down the Hatches - Benzinga
Nan Fung Trinity HK Ltd. Has $6.93 Million Position in Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can Immunome Inc. continue delivering strong returnsSwing Trade & Stepwise Trade Signal Guides - mfd.ru
Trading Recap: How do insiders feel about Immunome Inc2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Institutional Investors Are Immunome, Inc.'s (NASDAQ:IMNM) Biggest Bettors and Were Rewarded After Last Week's US$382m Market Cap Gain - 富途牛牛
Technical Analysis: Is TSHA part of any major indexTrade Analysis Report & Weekly Stock Performance Updates - baoquankhu1.vn
What are Immunome Incs recent SEC filings showingJuly 2025 Market Mood & Breakout Confirmation Trade Signals - baoquankhu1.vn
Immunome stock reaches 52-week high at $25.32 By Investing.com - Investing.com Australia
(IMNM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immunome (NASDAQ:IMNM) Hits New 12-Month HighWhat's Next? - MarketBeat
Immunome stock reaches 52-week high at $25.32 - Investing.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Teladoc (TDOC) and Immunome (IMNM) - The Globe and Mail
Nasdaq Moves: What is the long term forecast for Immunome Inc stockJuly 2025 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Sentiment Recap: Is Immunome Inc a good stock for dollar cost averaging2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA PlanWhat's Changed - simplywall.st
Bond Watch: Does Immunome Inc have declining or rising EPSEarnings Growth Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Immunome, Inc. (IMNM) Stock Analysis: A Promising Upside of Nearly 51% as Analysts Show Strong Support - DirectorsTalk Interviews
Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat SuccessHas The Bull Case Changed? - Yahoo Finance
Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance
Immunome, Inc. $IMNM Holdings Boosted by Nisa Investment Advisors LLC - MarketBeat
Is Immunome Inc affected by consumer sentiment2025 Retail Activity & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Wedbush Reiterates Outperform Rating for IMNM with $31 Price Tar - GuruFocus
Immunome (NASDAQ:IMNM) Trading 8.1% HigherHere's Why - MarketBeat
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Insider Monkey
Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush - MarketBeat
Assessing Immunome (IMNM) Valuation After Phase 3 Success And Upcoming J.P. Morgan Conference Presentation - Sahm
Returns Recap: Does Immunome Inc have declining or rising EPSWeekly Trade Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Responsive Playbooks and the IMNM Inflection - Stock Traders Daily
Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms - TechStock²
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunome Inc Azioni (IMNM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):